Flowers Foods delivered a third quarter that undercut the stabilization narrative it had been building. Adjusted EPS of $0.10 fell 37.5% short of the $0.15 consensus and below the $0.16 Earnings Whisper number, and earnings fell 56.5% from a year ago. Revenue of $1.169 billion missed the $1.19 billion consensus by 1.8% and declined 4.7% year over year. Management also cut its fiscal 2026 outlook for the second straight quarter. The miss matters, but the bigger change was in the conversation. The call moved away from a brand turnaround and toward protecting the balance sheet, with covenant relief, the dividend, and capital spending all now under discussion.

The top line shows the deterioration clearly. Pricing and mix added 2.3%, but volume fell 7.0%. In Branded Retail, volume dropped 8.6% against a 3.5% price/mix gain. Through 40 weeks, Branded Retail sales were down only 1.5%, so the third-quarter decline of 5.1% marks a sharp deceleration rather than a continuation of the earlier trend.

Margins absorbed the volume loss with little cushion:

• Production costs rose 120 basis points to 53.3% of sales, as lower volumes spread workforce costs over fewer units and the company bought more product from outside suppliers. Lower ingredient costs offset part of that.
• Adjusted SD&A climbed 160 basis points to 39.9% of sales on heavier marketing and higher logistics costs.
• Adjusted EBITDA fell 33.2% to $78.9 million, and the margin compressed from 9.6% to 6.8%.
• On a GAAP basis, diluted EPS was $0.07 versus $0.19 a year ago.

The revised guidance is arguably more telling than the quarter itself. Adjusted EPS guidance is now $0.63 to $0.68, down from $0.75 to $0.85. Adjusted EBITDA guidance is now $415 million to $430 million, down from $453 million to $481 million. Net sales are expected to fall 3.7% to 4.6%. Year-to-date adjusted EPS is already $0.59, so the new range implies only about $0.04 to $0.09 in the fourth quarter. That would mean another step down from an already weak third quarter.

The call explained why the recovery has stalled:

• CEO Ryals McMullian said improvement at the relaunched Nature's Own brand has been "slower than anticipated," particularly in loaf, where category units fell about 3%.
• Dave's Killer Bread units, which were growing as recently as the first quarter, are now declining. Management attributed this to GLP-1 drug use among higher-income consumers and to price sensitivity.
• Promotional intensity is high, and management described the effectiveness of promotions as uneven, especially in the mass channel.
• Commodity inflation is building in the fourth quarter as hedge coverage rolls off. Relief is not expected until the second half of 2027.
• Management declined to frame 2027 pricing.

The balance-sheet risk now sits at the center of the story. The 10-Q references seeking a covenant amendment, which management expects to secure before year-end. An analyst on the call noted that second-half EBITDA implies leverage above the covenant. That puts the first-quarter goal of leverage below 3x by the end of fiscal 2027 in doubt. Long-term debt stands at $1.68 billion against $72 million of cash. The dividend was already cut earlier in 2026, freeing roughly $100 million, and the board is reviewing it again. Management is also reviewing capex and brand investment for 2027. That creates an uncomfortable trade-off: protecting the balance sheet could starve the very initiatives meant to restore volume.

There are still genuine positives:

• Nature's Own share has improved sequentially since the relaunch.
• Smaller and half loaves, relaunched in the quarter, are showing early promising returns.
• Foodservice volume and sales grew on new business wins after a sales-force reorganization.
• A roughly $20 million cost takeout is expected to help in 2027.
• Third-quarter operating cash flow rose to $78.3 million from $54.4 million, and year-to-date operating cash flow was essentially flat at $319.9 million.

However, these improvements are small relative to an 8.6% branded volume decline and a 280-basis-point EBITDA margin contraction.

Investors were already skeptical, and they have become more so. Earnings Whispers investor sentiment fell from roughly neutral at -0.06 to -0.27, a meaningful move further into negative territory. As of the report date, shares traded at $6.01. That is 12.9% below the opening price after the August report and 23.2% below the 200-day moving average of $7.83. The AVWAP trend reading remains negative. In short, the market had been steadily discounting the recovery story well before this report confirmed that the recovery is running late.

The bottom line is that Flowers Foods did not just miss a quarter; it lost ground on its central thesis. Pricing is holding, but volume losses are accelerating, margins are compressing, and guidance implies an even weaker fourth quarter. Covenant pressure and a possible second dividend action now compete with brand investment for limited cash. The early Nature's Own and foodservice gains give the turnaround a pulse, but until volumes stabilize and the covenant question is resolved, bears have the stronger hand.